GLP-1 Receptor Agonists Linked to Fewer Fragility Fractures in Type 2 Diabetes

A new large analysis published in JAMA Network Open suggests that initiating GLP-1 receptor agonists (GLP-1s) is associated with a lower risk of fragility fractures in adults with type 2 diabetes, compared to starting DPP-4 inhibitors. This finding challenges previous assumptions that rapid weight loss from GLP-1s might increase fracture risk, indicating a potential bone-protective effect independent of weight loss and glycemic control.